...Kazuaki Okamoto; Hiroaki Nozawa; Shigenobu Emoto; Koji Murono; Kazuhito Sasaki; Soichiro Ishihara Introduction: Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic...

...) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received irinotecan and oxaliplatin (85 mg/m 2 ) on day 1, and capecitabine (1,000 mg/m 2 orally twice daily) on days 1–7 of a biweekly schedule...

... a chance of cure. The primary aim of this trial was to evaluate the response rate with intrahepatic oxaliplatin in combination with systemic 5-FU +/– cetuximab. Secondary aims were to evaluate the conversion rate from unresectable to resectable liver metastases, median progression-free survival, median...

... Delconte; Filippo de Braud; Vincenzo Mazzaferro; Maria Di Bartolomeo Objectives: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ...

...Berit Jordan; Franziska Jahn; Juliane Beckmann; Susanne Unverzagt; Carsten Müller-Tidow; Karin Jordan Objectives: The objective of this systematic review was to summarize the evidence of calcium and magnesium (CaMg) infusions in the prevention of oxaliplatin-induced neuropathy on the basis...

...Xin Shelley Wang; Qiuling Shi; Patrick M. Dougherty; Cathy Eng; Tito R. Mendoza; Loretta A. Williams; David R. Fogelman; Charles S. Cleeland Objective: We examined the emergence of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting toxicity of oxaliplatin, over the course...

...Marie Chaix; Julie Vincent; Véronique Lorgis; François Ghiringhelli Purpose: Fluoropyrimidines, oxaliplatin, irinotecan and targeted therapies represent the standard treatment of metastatic colorectal cancer. After failure of all these treatments, few options are available. In such chemorefractory...

...Sun Jin Park; Kil Yeon Lee; Won Seo Park; Sun Young Min Objective: We aimed to evaluate the clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer who developed mild hypersensitivity reactions (HSRs). Methods: A retrospective review was performed of 204 patients who...

... following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC). Methods: Patients received either bevacizumab (7.5 mg/kg) + XELOX (capecitabine 1,000 mg/m 2 twice daily on days 1-14...

...; Tuğba Köş; Necati Alkış; Halit Karaca; Nazım Serdal Turhal; Nurullah Zengin; Anatolian Society of Medical Oncology Objective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Colorectal cancer Oxaliplatin Irinotecan FOLFOX6 FOLFIRI FIREFOX Neurotoxicity Patients received an alternating regimen of 4 cycles of mFOLFOX-6 (85 mg/m 2 oxaliplatin, 200...

... to Child-Pugh A cirrhotic patients. The biweekly combination of gemcitabine and oxaliplatin (GEMOX) is safe and widely used in patients with advanced malignancies. We aimed to evaluate the feasibility of GEMOX in HCC patients with Child-Pugh B cirrhosis ineligible for sorafenib. Methods: The medical...

... markers may predict the prognosis of advanced colorectal cancer (CRC) patients receiving palliative chemotherapy. Methods: The study population included 50 patients with far advanced or recurrent unresectable CRC who received oxaliplatin-based combination chemotherapy as first-line treatment in our...

... (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer. Methods: This phase I dose-finding study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD) or both of FOLFOXIRI. Patients with UDP-glucuronosyltransferase...

... an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection...

... survival (OS) in metastatic colorectal cancer (MCRC) patients who underwent oxaliplatin-based chemotherapy remains controversial. Methods: We retrospectively analyzed 331 patients with MCRC who underwent first-line oxaliplatin-based chemotherapy. Treatment outcomes were compared between patients who...

... within the gastrointestinal tract, respectively. The study was designed to identify the maximum tolerable dose and the dose-limiting toxicities of two schedules of S-1 combined with oxaliplatin and bevacizumab, in advanced solid tumor patients. Methods: Schedule A: S-1 was administered orally at 20 mg/m...

... were treated with cetuximab in combination with gemcitabine and oxaliplatin until disease progression. Analyses of the EGFR pathway, including KRAS mutations, could be performed in 25 patients. Analyses were carried out following microdissection of the tumor. Results: Fourteen (56%) of the 25 patients...

...K. Amarantidis; N. Xenidis; L. Chelis; E. Chamalidou; P. Dimopoulos; P. Michailidis; A. Tentes; S. Deftereos; M. Karanikas; A. Karayiannakis; S. Kakolyris Objective: In the present phase II study, we evaluated the efficacy and safety of a docetaxel-oxaliplatin-capecitabine combination as a first...

...Elias Assaf; Muriel Verlinde-Carvalho; Catherine Delbaldo; Julien Grenier; Zineb Sellam; Damien Pouessel; Linda Bouaita; Isabelle Baumgaertner; Iradj Sobhani; Claude Tayar; Muriel Paul; Stéphane Culine Background: To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5...